BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-1.89%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$14.7B
AUM Growth
+$14.7B
(-5.8%)
Cap. Flow
-$316M
Cap. Flow
% of AUM
-2.15%
Top 10 Holdings %
Top 10 Hldgs %
84.38%
Holding
107
New
11
Increased
15
Reduced
16
Closed
4
Top Buys
| 1 |
BCEL
Atreca, Inc. Class A Common Stock
BCEL
|
$66.6M |
| 2 |
Adaptive Biotechnologies
ADPT
|
$56.3M |
| 3 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$29.4M |
| 4 |
Neurocrine Biosciences
NBIX
|
$26.7M |
| 5 |
Heron Therapeutics
HRTX
|
$18.6M |
Top Sells
| 1 |
Incyte
INCY
|
$195M |
| 2 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
$97.2M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$68.7M |
| 4 |
GHDX
Genomic Health, Inc.
GHDX
|
$54.6M |
| 5 |
ARRY
Array Biopharma Inc
ARRY
|
$46M |
Sector Composition
| 1 | Healthcare | 94.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRIL
101
DELISTED
Trillium Therapeutics Inc.
TRIL
| $166K | ﹤0.01% |
505,262
| – | – |
|
|
CMTA
102
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| – | – |
-3,724,445
| Closed | -$97.2M |
|
|
CFRX
103
DELISTED
ContraFect Corporation
CFRX
| – | – |
-2,914,536
| Closed | -$1.16M |
|
104
MacroGenics
MGNX
$121M
| – | – |
-302,600
| Closed | -$5.44M |
|
105
InflaRx
IFRX
$117M
| – | – |
-178,987
| Closed | -$6.76M |
|